18th Annual BHIVA Conference, 18-20 April 2012, UK
1 June 2012. Related: Conference reports.
2012
Half of gay men in London would chose oral PrEP to reduce risk of HIV
1 June 2012. Related: Conference reports, HIV prevention and transmission.
Recent infection is common in UK; 30% gay men aged 15-25 infected within a year of diagnosis
1 June 2012. Related: Conference reports, HIV prevention and transmission.
One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated
1 June 2012. Related: Conference reports, Side effects, Coinfections and complications.
Hodgkin’s lymphoma: survival normalises to HIV negative rates despite more advanced disease at diagnosis
1 June 2012. Related: Conference reports, Coinfections and complications.
Promising outcomes from laser ablative treatment of AIN2/3 to prevent anal cancer
1 June 2012. Related: Conference reports, Coinfections and complications, Cancer and HIV.
KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addition to ART
1 June 2012. Related: Conference reports, Coinfections and complications.
3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines
1 June 2012. Related: Conference reports, HIV prevention and transmission.
Stavudine (d4T) phase-out festival in Delhi
1 June 2012. Related: Treatment access.
Case reports of complications from ketamine use in two MSM on ritonavir-based combinations
1 June 2012. Related: Conference reports, PK and drug interactions.
Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations
1 June 2012. Related: Conference reports, PK and drug interactions, Side effects.
Outcomes from switches to atazanavir/r in London
1 June 2012. Related: Conference reports, Antiretrovirals, Side effects.
Intimate partner violence towards HIV positive women in the UK
1 June 2012. Related: Conference reports, Women's health.
13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona
1 June 2012. Related: Conference reports, PK and drug interactions.
20% people switch Atripla due to efavirenz side effects: late switches are common
1 June 2012. Related: Side effects.
New UK guidelines: Treatment of HIV-1 positive adults with antiretroviral therapy (2012)
1 June 2012. Related: Guidelines.
Studies on pipeline ARVs
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
New UK guidelines: Management of HIV infection in pregnant women (2012)
1 June 2012. Related: Pregnancy, Guidelines.
WHO guidelines for testing, counselling and treatment in serodifferent couples (April 2012): ART at CD4 >350 to reduce transmission
1 June 2012. Related: Guidelines, HIV prevention and transmission.
NICE guideline on fertility treatment proposes alternatives to sperm washing (2012)
1 June 2012. Related: Guidelines, HIV prevention and transmission.
ACT-UP at 25: tax Wall Street, end AIDS
1 June 2012. Related: Other news.
Fosamprenavir paediatric dosing approved in US for ages 4 weeks to <6 years
1 June 2012. Related: Antiretrovirals.
FDA advisory panel vote 13:1 for approval of Quad
1 June 2012. Related: Antiretrovirals.
Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort
1 June 2012. Related: Side effects.
FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US
1 June 2012. Related: Treatment access.
FDA advisory hearing supports approval of tenofovir/FTC for PrEP
1 June 2012. Related: Antiretrovirals.
Associations between tenofovir use and renal complications in VA cohort
1 June 2012. Related: Side effects.
Washout pharmacokinetics of transplacental raltegravir in neonates
1 June 2012. Related: Conference reports, PK and drug interactions.
Interactions between malaria drugs and etravirine or darunavir/r
1 June 2012. Related: Conference reports, PK and drug interactions.
No interaction between antimalarial amodiaquine and nevirapine
1 June 2012. Related: Conference reports, PK and drug interactions.
Pharmacokinetics of atazanavir/ritonavir plus raltegravir
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Atazanavir/ritonavir and voriconazole not to be coadministered
1 June 2012. Related: Conference reports, PK and drug interactions.
Milk thistle (silymarin) and darunavir/ritonavir
1 June 2012. Related: Conference reports, PK and drug interactions.
Echinacea and etravirine
1 June 2012. Related: Conference reports, PK and drug interactions.
Warfarin and ARVs: impact of African American race and ritonavir
1 June 2012. Related: Conference reports, PK and drug interactions.
19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012, Seattle
1 June 2012. Related: Conference reports.
HIV and the brain: longitudinal results from CHARTER and other studies
1 June 2012. Related: Conference reports, Coinfections and complications.
Systolic blood pressure and risk of myocardial infarction in HIV infection
1 June 2012. Related: Conference reports, Coinfections and complications.
Risk of non-AIDS defining malignancies and immune suppression
1 June 2012. Related: Conference reports, Coinfections and complications.
Renal impairment in the D:A:D study
1 June 2012. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Early data for rilpivirine long acting formulation supports further investigation for PrEP
1 June 2012. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Hormonal contraception: HIV transmission and progression rates
1 June 2012. Related: Conference reports, Women's health.
Darunavir use during pregnancy
1 June 2012. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
Volume 13 Number 5/6 May/June 2012 PDF
1 June 2012. Related: PDFs.
Global action over the challenge to India
2 April 2012. Related: Treatment access.
19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012
1 April 2012. Related: Conference reports.
Cure research takes centre stage: proof of concept for activating the latent reservoir
1 April 2012. Related: Conference reports, Cure-related research, Basic science and immunology.
Quad fixed-dose integrase combination: phase 3 studies at week 48
1 April 2012. Related: Conference reports, Antiretrovirals.
Dolutegravir studies continue to show promise
1 April 2012. Related: Conference reports, Antiretrovirals, Pregnancy.
Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation
1 April 2012. Related: Conference reports, Antiretrovirals.
Paediatric formulations of ARVs: including an exciting new class
1 April 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART
1 April 2012. Related: Conference reports, Paediatric care.
High prevalence of d4T-associated lipodystrophy including lipoatrophy in children
1 April 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Lopinavir/ritonavir monotherapy in children
1 April 2012. Related: Conference reports, Paediatric care.
Stopping treatment after early ART in infants
1 April 2012. Related: Conference reports, Paediatric care.
Supplement: i-Base Introduction to Combination Therapy
1 April 2012. Related: Special reports.
Volume 13 Number 3/4 March/April 2012
1 April 2012. Related: Editorial.
PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection
1 April 2012. Related: Conference reports, HIV prevention and transmission.
Risk of HIV reinfection may be similar to risk of initial HIV infection
1 April 2012. Related: Conference reports, HIV prevention and transmission.
Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus
1 April 2012. Related: Conference reports, HIV prevention and transmission.
No association between atazanavir and MI or stroke in D:A:D study
1 April 2012. Related: Conference reports, Side effects, Coinfections and complications.
Hepatitis C coinfection studies
1 April 2012. Related: Conference reports, Hepatitis coinfection.
Herpes Zoster vaccine safe and effective in HIV positive people
1 April 2012. Related: Conference reports, Vaccines and microbicides.
High dose flu vaccine improves antibody responses in HIV positive people
1 April 2012. Related: Conference reports, Vaccines and microbicides.
Dolutegravir Expanded Access Programme
1 April 2012. Related: Antiretrovirals.